関連する実験動画
Updated: May 1, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.7K
人間のP2Y12受容体の構造は,抗血栓性薬との複合体である
Kaihua Zhang1, Jin Zhang1, Zhan-Guo Gao2
11] CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, China [2].
Nature
|March 28, 2014
まとめ
研究者らは,AZD1283.3に結合するP2Y12受容体 (P2Y12R) の結晶構造を決定した. これは,ユニークな構造的特徴を明らかにし,抗血栓性療法のための新しいP2Y12R阻害剤を開発するための洞察を提供します.
科学分野:
- バイオケミストリーと構造生物学
- 薬理学 薬理学とは
- 心血管研究に関する研究.
背景:
- P2Y受容体 (P2YRs) は,細胞外核酸によって活性化されるGタンパク質結合受容体である.
- P2Y12Rは,血小板活性化と血栓形成の重要な調節体であり,クロピドグレルやチカグレロールなどの抗血栓薬によって標的とされています.
- 現在のP2Y12R阻害剤には限界があり,新しい薬候補薬剤の必要性を強調しています.
研究 の 目的:
- P2Y12R関数の構造的基礎を解明する.
- 新しいP2Y12R阻害剤の開発のための洞察を提供するために.
- 非核酸リバーシブルアンタゴニストであるAZD1283のP2Y12Rとの結合を特徴づける.
主な方法:
- 2.6 Å の解像度のX線結晶学.
- AZD1283.3との複合体におけるヒトP2Y12R構造の決定
- リガンド結合部位と受容体構成の構造分析.
主要な成果:
- AZD1283との複合体におけるヒトP2Y12Rの結晶構造が決定されました.
- ヘリックスVのユニークな直線形状が観察され,P2Y12Rを他のクラスAのGPCRと区別しました.
- AZD1283の結合は,ダイナミックな二硫化物ブリッジを明らかにし,潜在的な二重リガンド結合ポケットを特定しました.
結論:
- 決定された構造は,P2Y12Rのアーキテクチャとリガンドの相互作用に関する重要な洞察を提供します.
- この構造情報は,改良されたP2Y12Rリガンドとアロステル調節器の設計に不可欠です.
- この発見は,潜在的に強化されたプロファイルを持つ次世代の抗血栓性薬の開発への道を開く.
関連する概念動画
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:29Drug-Receptor Interactions
8.3K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
8.3K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:28Structure-Activity Relationships and Drug Design
1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
01:30Drug Binding to Blood Components
666
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
666